AB0554 CLINICAL CHARACTERISTICS AND BURDEN AMONG PATIENTS WITH SLE STRATIFIED BY SLEDAI DERIVED SEVERITY: RESULTS FROM A REAL-WORLD STUDY IN THE US

Background Data are limited concerning the distribution of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores among patients with SLE in clinical practice and characteristics specific SLEDAI scores. Objectives To investigate patient demographics, status, treatment patterns, reported outcomes (PROs), overall stratified by score. Methods were drawn from Adelphi Real World IV (2021) Specific Programme™, a point-in-time survey 79 US rheumatologists SLE. Rheumatologists completed questionnaires regarding treatment. The same invited to complete containing EuroQoL 5-Dimensions (EQ-5D), Functional Assessment Chronic Illness Therapy Fatigue Subscale (FACIT-Fatigue) Work Productivity & Impairment questionnaire (WPAI) Patient-Reported Outcomes (PRO) tools. Physicians 24 questions based on SLEDAI-2K their patients’ current manifestations, which score was derived 1 . Patients grouped score: SLEDAI=0 (none), SLEDAI=1-6 (mild), SLEDAI=7-12 (moderate), SLEDAI>12 (severe) 2 without rheumatologist-perceived renal organ involvement ≥ year duration included for analysis using bivariate tests. Results A total 273 this analysis. Mean [SD] age 47.0[14.2] years, 83.9% female, 57.1% White/Caucasian, 24.9% African American. Table 1. Point-in-time patterns PROs Total Sample (n=273) (n=60, 22%) (n=79, 28.9%) (n=70, 25.6%) (n=64, 23.4%) p value Physician-Reported Clinical Status Treatment History Current severity, n(%) Mild 221 (81.0) 51 (85.0) 70 (88.6) 53 (75.7) 47 (73.4) 0.057 Moderate 49 (18.0) 9 (15.0) (11.4) 16 (22.9) 15 (23.4) Severe 3 (1.1) 0 (0.0) (1.4) (3.1) joint symptoms, Joint tenderness 109 (39.9) (40.0) 27 (34.2) 28 30 (46.9) 0.498 stiffness 121 (44.3) 22 (36.7) 33 (41.8) 37 (52.9) 29 (45.3) 0.293 swelling 60 (22.0) 17 (28.3) 13 (16.5) 19 (27.1) 11 (17.2) 0.190 Flares last 12 months 1.6 [1.5] 1.3 [1.2] 1.7 [1.7] 1.5 [1.3] 1.8 0.550 Currently prescribed, Belimumab 58 (21.3) 14 (23.3) 18 (12.9) 8 (10.1) (21.4) 0.011 Immunosuppressants 48 (17.6) 7 (11.7) 26 (18.6) 10 (12.7) 0.052 Corticosteroids 138 (50.6) 35 (58.3) 62 32 (45.7) 0.003 Antimalarials 206 (75.5) (46.7) 108 (77.1) 64 59 (84.3) <0.001 EQ5D-5L Utility (0=death 1= full health) 0.79 [0.19] 0.83 [0.12] 0.82 [0.21] [0.14] 0.69 [0.25] 0.024 FACIT-Fatigue (0=worst fatigue 52= no fatigue) 32.7 [12.2] 36.8 [8.7] 36.1 [12.5] 29.1 [9.8] 26.4 [14.3] WPAI (0= impact 100= completely impacted) 26.8 [21.2] 25.2 [15.8] 19.5 [23.6] 35.7 [20.2] 31.9 [26.7] 0.131 49% categorized as 7-12 or >12 (moderate severe). Among (moderate) patients, 75.7% subjectively physician having mild Of (severe), 73.4% Joints symptoms flaring not significantly different across groups. greater lower EQ5D There statistical difference between Conclusion disconnect physician-perceived severity exists. SLE, irrespective SLEDAI, had high prevalence but higher impacted quality life. References [1]Gladman D et al., Journal Rheumatology, 2002. [2]Fanouriakis Annals rheumatic diseases , 2019. Disclosure Interests Aisha Vadhariya Employee of: Eli Lilly Company, Julie Birt Shareholder Jianmin Wu Kirstin Griffing Fiona Bailey: None declared, James Hetherington: Elke Rottier: Sophie Barlow: Karen Costenbader Consultant Lilly, Astra Zeneca, Janssen, Amgen, Glaxo Smith Kline, Grant/research support from: Exagen, Gilead, Merck